Loading...
•
Dec 31, 2022
Mirum Pharmaceuticals Q4 2022 Earnings Report
Mirum Pharmaceuticals reported its Q4 2022 financial results and provided a business update.
Key Takeaways
Mirum Pharmaceuticals reported total revenue of $27.91 million for the fourth quarter of 2022, driven by net product sales of LIVMARLI, and ended the year with $251.7 million in cash, cash equivalents, restricted cash equivalents, and short-term investments.
Fourth quarter 2022 net sales grew 48% as compared to third quarter 2022.
U.S. business positioned for 50% net product sales growth in 2023.
Launched LIVMARLI in Germany in early 2023 following European Commission approval.
Submitted a supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for LIVMARLI PFIC.
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Mirum Pharmaceuticals Revenue by Segment
Revenue by Segment
Product Sales, Net Revenue
CapyFin.com Forward Guidance
Mirum Pharmaceuticals anticipates a transformative year in 2023, with potential label expansion into PFIC and data milestones for other late-stage clinical programs.
Positive Outlook
- Continued commercial success for LIVMARLI
- Growth in year over year net product sales
- Planned LIVMARLI launches in additional international markets
- Label expansion into PFIC
- Becoming a global leader in rare disease
Challenges Ahead
- Risks and uncertainties associated with Mirum’s business in general
- Impact of the COVID-19 pandemic
- Risks described in Mirum’s filings with the Securities and Exchange Commission
- Uncertainties regarding results, conduct and progress of Mirum’s ongoing and planned studies for its product candidates
- Uncertainties regarding the regulatory approval path for its product candidates globally.